Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field.COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).

Challenges in Using Circulating Micro-RNAs as Biomarkers for Cardiovascular Diseases

“…Cardiovascular diseases (CVDs) are one of the leading causes of death in developed countries, highlighting the need to identify novel prognostic and diagnostic biomarkers for the prevention and treatment of such diseases [1,2]. However, the identification of reliable biomarkers that could routinely be measured in serum or plasma remains a major challenge in CVDs [3].…”

OMICS approaches in cardiovascular diseases: a mini review

“…Furthermore, quantitative real-time polymerase chain reaction (qPCR) with high throughput arrange-ment of computational biology gives a rigid strength to the microarray where RNA-Seq approaches give the entire information of complete RNA profiling. These inclusive approaches of transcriptomics disclose the way of identification, progression, and treatment of CVDs [35]. However, a recent study gives a picture of bioinformatics approaches through NGS platforms used in transcriptomics.…”

A Year in the Life of the EU-CardioRNA COST Action: CA17129 Catalysing Transcriptomics Research in Cardiovascular Disease

“…Under the umbrella of this common theme, members and participants in WG1 have a diverse range of expertise including bioinformatics, clinical research and biostatistics, biochemistry, molecular biology and experimental cardiology (pre-clinical models). In accordance with the goals of the EU-CardioRNA COST Action, the interdisciplinary nature of WG1 aims to accelerate translation of experimental data into clinical applications [1].…”

“…Emma Robinson kick-started the session with updates on Science Communication and Dissemination. Primarily, our Memorandum of Understanding (MoU)-based EU-CardioRNA project report, 'Catalysing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129,' was published on 29 March 2019 [1]. From the NcRNA journal (MDPI) webpage, the article had been viewed 1695 times and downloaded 999 times (metrics as of 16 October 2019).…”